587 related articles for article (PubMed ID: 22025163)
1. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
Yap TA; Yan L; Patnaik A; Fearen I; Olmos D; Papadopoulos K; Baird RD; Delgado L; Taylor A; Lupinacci L; Riisnaes R; Pope LL; Heaton SP; Thomas G; Garrett MD; Sullivan DM; de Bono JS; Tolcher AW
J Clin Oncol; 2011 Dec; 29(35):4688-95. PubMed ID: 22025163
[TBL] [Abstract][Full Text] [Related]
2. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
[TBL] [Abstract][Full Text] [Related]
3. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors.
Krop I; Demuth T; Guthrie T; Wen PY; Mason WP; Chinnaiyan P; Butowski N; Groves MD; Kesari S; Freedman SJ; Blackman S; Watters J; Loboda A; Podtelezhnikov A; Lunceford J; Chen C; Giannotti M; Hing J; Beckman R; Lorusso P
J Clin Oncol; 2012 Jul; 30(19):2307-13. PubMed ID: 22547604
[TBL] [Abstract][Full Text] [Related]
4. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.
Yap TA; Yan L; Patnaik A; Tunariu N; Biondo A; Fearen I; Papadopoulos KP; Olmos D; Baird R; Delgado L; Tetteh E; Beckman RA; Lupinacci L; Riisnaes R; Decordova S; Heaton SP; Swales K; deSouza NM; Leach MO; Garrett MD; Sullivan DM; de Bono JS; Tolcher AW
Clin Cancer Res; 2014 Nov; 20(22):5672-85. PubMed ID: 25239610
[TBL] [Abstract][Full Text] [Related]
5. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
[TBL] [Abstract][Full Text] [Related]
6. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
Rosen LS; Kurzrock R; Mulay M; Van Vugt A; Purdom M; Ng C; Silverman J; Koutsoukos A; Sun YN; Bass MB; Xu RY; Polverino A; Wiezorek JS; Chang DD; Benjamin R; Herbst RS
J Clin Oncol; 2007 Jun; 25(17):2369-76. PubMed ID: 17557949
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study.
Fouladi M; Perentesis JP; Phillips CL; Leary S; Reid JM; McGovern RM; Ingle AM; Ahern CH; Ames MM; Houghton P; Doyle LA; Weigel B; Blaney SM
Pediatr Blood Cancer; 2014 Jul; 61(7):1246-51. PubMed ID: 24664955
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
Molife LR; Yan L; Vitfell-Rasmussen J; Zernhelt AM; Sullivan DM; Cassier PA; Chen E; Biondo A; Tetteh E; Siu LL; Patnaik A; Papadopoulos KP; de Bono JS; Tolcher AW; Minton S
J Hematol Oncol; 2014 Jan; 7():1. PubMed ID: 24387695
[TBL] [Abstract][Full Text] [Related]
11. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.
Zhao YY; Tian Y; Zhang J; Xu F; Yang YP; Huang Y; Zhao HY; Zhang JW; Xue C; Lam MH; Yan L; Hu ZH; Dinglin XX; Zhang L
Drug Des Devel Ther; 2014; 8():1827-37. PubMed ID: 25336925
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
Gupta S; Argilés G; Munster PN; Hollebecque A; Dajani O; Cheng JD; Wang R; Swift A; Tosolini A; Piha-Paul SA
Clin Cancer Res; 2015 Dec; 21(23):5235-44. PubMed ID: 26187616
[TBL] [Abstract][Full Text] [Related]
13. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
Hofheinz RD; Al-Batran SE; Hochhaus A; Jäger E; Reichardt VL; Fritsch H; Trommeshauser D; Munzert G
Clin Cancer Res; 2010 Sep; 16(18):4666-74. PubMed ID: 20682708
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Weekes CD; Von Hoff DD; Adjei AA; Leffingwell DP; Eckhardt SG; Gore L; Lewis KD; Weiss GJ; Ramanathan RK; Dy GK; Ma WW; Sheedy B; Iverson C; Miner JN; Shen Z; Yeh LT; Dubowy RL; Jeffers M; Rajagopalan P; Clendeninn NJ
Clin Cancer Res; 2013 Mar; 19(5):1232-43. PubMed ID: 23434733
[TBL] [Abstract][Full Text] [Related]
16. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
Munster PN; Britten CD; Mita M; Gelmon K; Minton SE; Moulder S; Slamon DJ; Guo F; Letrent SP; Denis L; Tolcher AW
Clin Cancer Res; 2007 Feb; 13(4):1238-45. PubMed ID: 17317835
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.
Mross K; Frost A; Steinbild S; Hedbom S; Rentschler J; Kaiser R; Rouyrre N; Trommeshauser D; Hoesl CE; Munzert G
J Clin Oncol; 2008 Dec; 26(34):5511-7. PubMed ID: 18955456
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.
Olmos D; Barker D; Sharma R; Brunetto AT; Yap TA; Taegtmeyer AB; Barriuso J; Medani H; Degenhardt YY; Allred AJ; Smith DA; Murray SC; Lampkin TA; Dar MM; Wilson R; de Bono JS; Blagden SP
Clin Cancer Res; 2011 May; 17(10):3420-30. PubMed ID: 21459796
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
20. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
